# Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct07586124/  
OnCo record `nct07586124` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pucotenlimab in head and neck squamous cell carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07586124 by Lepu Biopharma Co., Ltd., with 80 participants planned, started 2026-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: Becotatug Vedotin for Injection, Placebo, Pucotenlimab Injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07586124
- Phase: 2
- Setting: A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of Pucotenlimab Injection Combined With Becotatug Vedotin for Injection as Perioperative Therapy in Participants With Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07586124: https://clinicaltrials.gov/study/NCT07586124

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07586124.json